Thursday 7 May, 2026
Introduction: Active metabolites of drugs under clinical development require evaluation of their quantitative and qualitative contributions to the overall pharmacological…
Read morePoster: Drug/Disease Modelling - Infection
Modelling pharmacokinetic-pharmacodynamic of PBTZ169 in glycerol and cholesterol using CFU and MPN as biomarkers
Thursday 7 May, 2026
Introduction/Objectives: Mycobacterium tuberculosis undergoes metabolic and physiological adaptations to survive in the diverse microenvironments of granulomas and cavities within the…
Read moreLinezolid Pharmacokinetics in Adults with Rifampicin-Resistant TB: Impact of Pregnancy and Lactation
Thursday 7 May, 2026
Objectives Rifampicin-resistant tuberculosis (RR-TB) is a global health concern, with approximately 400 000 incident cases annually1. Linezolid is part of…
Read moreTRANSLATIONAL PKPD MODELLING FRAMEWORK TO SUPPORT PRIORITISATION OF NOVEL TUBERCULOSIS REGIMENS WITHIN THE PARADIGM4TB PLATFORM.
Thursday 7 May, 2026
Introduction: The development of novel tuberculosis (TB) combination regimens is constrained by long, resource-intensive clinical trials and limited quantitative evaluation…
Read moreEFFECT OF METFORMIN ON THE PHARMACOKINETICS OF RIFAMPICIN, ISONIAZID, AND PYRAZINAMIDE IN ADULTS WITH TB AND HIV
Thursday 7 May, 2026
Objective Tuberculosis (TB) remains the leading infectious cause of death, particularly among people with HIV (1,2). Metformin is being investigated…
Read morePOPULATION PHARMACOKINETICS OF BICTEGRAVIR CO-ADMINISTERED WITH RIFAMPICIN IN ADULTS WITH HIV AND TUBERCULOSIS
Thursday 7 May, 2026
Introduction: Bictegravir is an integrase strand transfer inhibitor (INSTI), and a key component of Biktarvy®, a fixed-dose combination containing 50…
Read morePopulation Pharmacokinetic Modelling of Plasma and Intracellular Bictegravir in People Living with HIV
Thursday 7 May, 2026
Objectives Bictegravir is a second-generation human immunodeficiency virus (HIV) integrase strand transfer inhibitor (INSTI) widely used in first-line antiretroviral therapy[1]….
Read moreA multi-compartment QSP model of hepatitis B infection linking viral life cycle and immune regulation to support model-informed therapy evaluation
Thursday 7 May, 2026
Objectives: Chronic hepatitis B (CHB) remains a major global health burden, and functional cure (sustained HBsAg loss off therapy) is…
Read morePOPULATION PHARMACOKINETICS AND PHARMACOGENOMICS OF ETHAMBUTOL IN AN AFRICAN COHORT WITH DRUG RESISTANT PULMONARY TUBERCULOSIS
Thursday 7 May, 2026
Objectives: Ethambutol is a first-line antitubercular drug included in World Health Organization recommended regimen for tuberculosis (TB) and is also…
Read moreA Translational Multiscale Model Integrating Immune Response, Bacterial Dynamics, and Lung PBPK to Predict Tuberculosis Treatment Response
Thursday 7 May, 2026
Objectives Tuberculosis (TB) treatment requires prolonged multidrug therapy and exhibits substantial variability in response across patients. Treatment outcomes are determined…
Read more